Delta sleep-inducing peptide in normal humans and in patients with sleep apnea and narcolepsy.
We measured morning plasma concentrations of delta sleep-inducing-peptide-like-immunoreactivity (DSIP-LI) in 9 sleep apnea patients, 10 narcolepsy patients, and 11 normal controls. Comparisons between the three groups showed no significant differences, although there was a trend toward association with low levels of DSIP-LI in the narcoleptic group, particularly in patients not using medications. No differences were found in the morning or evening plasma DSIP-LI levels in a second group of 11 normal controls and 8 sleep apneics. Our findings do not appear to support a biological marker role of disease activity for single measures of plasma DSIP in sleep apnea.
Department of Psychiatry, Pennsylvania State University, Hershey 17033, USA.
A N
AN
Vgontzas
T C
TC
Friedman
G P
GP
Chrousos
E O
EO
Bixler
A
A
Vela-Bueno
A
A
Kales
D000328:Adult; D000595:Amino Acid Sequence; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D003701:Delta Sleep-Inducing Peptide / Q000097:blood* / Q000737:chemistry; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D008969:Molecular Sequence Data; D009290:Narcolepsy / Q000097:blood* / Q000503:physiopathology; D012891:Sleep Apnea Syndromes / Q000097:blood* / Q000503:physiopathology; D012894:Sleep Stages / Q000502:physiology
D015415:Biomarkers; D003701:Delta Sleep-Inducing Peptide